Predictors of guideline treatment nonadherence and the impact on survival in patients with colorectal cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 13, Issue 1, 2015, Pages 51-60

  Hines, Robert B ^a   Barrett, Alina ^b   Twumasi Ankrah, Philip ^a   Broccoli, Dominique ^b   Engelman, Kimberly K ^c   Baranda, Joaquina ^c   Ablah, Elizabeth A ^a   Jacobson, Lisette ^a   Redmond, Michelle ^a   Tu, Wei ^d   Collins, Tracie C ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b MEMORIAL HEALTH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^d GEORGIA SOUTHERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGE; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER SURVIVOR; COHORT ANALYSIS; COLORECTAL CANCER; COMORBIDITY; ELIXHAUSER COMORBIDITY INDEX; FEMALE; FOLLOW UP; HEALTH IMPACT ASSESSMENT; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICALLY UNINSURED; MEDICARE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PATIENT RISK; PRACTICE GUIDELINE; PREDICTOR VARIABLE; PROGNOSTIC ASSESSMENT; RACE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SURVIVAL TIME; SYSTEMIC THERAPY; TOTAL QUALITY MANAGEMENT; TREATMENT REFUSAL; CANCER GRADING; CAUSE OF DEATH; COLORECTAL NEOPLASMS; GEORGIA (REPUBLIC); MORTALITY; PROGNOSIS; REGISTER; RISK; RISK FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CAUSE OF DEATH; COLORECTAL NEOPLASMS; COMORBIDITY; FEMALE; GEORGIA (REPUBLIC); GUIDELINE ADHERENCE; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; ODDS RATIO; PROGNOSIS; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84921522679     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2015.0008     Document Type: Article

References (86)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. American Cancer Society. Colorectal Cancer Facts & Figures 2011-2013. Atlanta, GA: American Cancer Society; 2011. Available at: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-028323.pdf. Accessed December 2, 2014.
3. American Cancer Society. Cancer Facts & Figures 2013. Atlanta, GA: American Cancer Society; 2013. Available at: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf. Accessed December 2, 2014.
4. Voices of a broken system: real people, real problems. Presiden't Cancer Panel Report. Bethesda, MD: National Institutes of Health, National Cancer Institute; 2001. Available at: http://deainfo.nci.nih.gov/advisory/pcp/archive/pcp00-01rpt/PCPvideo/voices-files/PDFfiles/PCPbook.pdf. Accessed December 2, 2014.
5. Hewitt ME, Simone JV, eds. Ensuring quality cancer care. Washington, D.C.: National Academy Press; 1999. Available at: http://www.nap.edu/openbook.php?record-id=6467. Accessed December 2, 2014.
6. Benson AB III, Venook AP, Bekaii-Saab T, et al. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 2.2015. Available at: NCCN.org. Accessed December 2, 2014.
7. Benson AB III, Venook AP, Bekaii-Saab T, et al. NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer. Version 1.2015. Available at: NCCN.org. Accessed December 2, 2014.
8. Boland GM, Chang GJ, Haynes AB, et al. Association between adherence to National Comprehensive Cancer Network treatment guidelines and improved survival in patients with colon cancer. Cancer 2013;119:1593-1601.
9. Chagpar R, Xing Y, Chiang YJ, et al. Adherence to stage-specific treatment guidelines for patients with colon cancer. J Clin Oncol 2012;30:972-979.
10. Fitzgerald TL, Biswas T, O'Brien K, et al. Neoadjuvant radiotherapy for rectal cancer: adherence to evidence-based guidelines in clinical practice. World J Surg 2013;37:639-645.
11. Fitzgerald TL, Zervos E, Wong JH. Patterns of pelvic radiotherapy in patients with stage II/III rectal cancer. J Cancer Epidemiol 2013;2013:408460.
12. Jessup JM, Stewart A, Greene FL, Minsky BD. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA 2005;294:2703-2711.
13. Mak RH, McCarthy EP, Das P, et al. Adoption of preoperative radiation therapy for rectal cancer from 2000 to 2006: a Surveillance, Epidemiology, and End Results Patterns-of-Care Study. Int J Radiat Oncol Biol Phys 2011;80:978-984.
14. Iwashyna TJ, Lamont EB. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer. J Clin Oncol 2002;20:3992-3998.
15. Popescu RA, Norman A, Ross PJ, et al. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 1999;17:2412-2418.
16. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001;345:1091-1097.
17. Zuckerman IH, Rapp T, Onukwugha E, et al. Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with stage III colon cancer. J Am Geriatr Soc 2009;57:1403-1410.
18. Piccirillo JF, Vlahiotis A, Barrett LB, et al. The changing prevalence of comorbidity across the age spectrum. Crit Rev Oncol Hematol 2008;67:124-132.
19. Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer 1997;80:1273-1283.
20. Lee L, Cheung WY, Atkinson E, Krzyzanowska MK. Impact of comorbidity on chemotherapy use and outcomes in solid tumors: a systematic review. J Clin Oncol 2011;29:106-117.
21. Gross CP, McAvay GJ, Krumholz HM, et al. The effect of age and chronic illness on life expectancy after a diagnosis of colorectal cancer: implications for screening. Ann Intern Med 2006;145:646-653.
22. Cascinu S. Adjuvant chemotherapy in colon cancer: can we improve quality of care? Dig Liver Dis 2013;45:637-638.
23. Baldwin LM, Dobie SA, Billingsley K, et al. Explaining black-white differences in receipt of recommended colon cancer treatment. J Natl Cancer Inst 2005;97:1211-1220.
24. Demissie K, Oluwole OO, Balasubramanian BA, et al. Racial differences in the treatment of colorectal cancer: a comparison of surgical and radiation therapy between Whites and Blacks. Ann Epidemiol 2004;14:215-221.
25. Roetzheim RG, Pal N, Gonzalez EC, et al. Effects of health insurance and race on colorectal cancer treatments and outcomes. Am J Public Health 2000;90:1746-1754.
26. Hines RB, Markossian TW. Differences in late-stage diagnosis, treatment, and colorectal cancer-related death between rural and urban African Americans and whites in Georgia. J Rural Health 2012;28:296-305.
27. McGory ML, Zingmond DS, Sekeris E, et al. A patient's race/ethnicity does not explain the underuse of appropriate adjuvant therapy in colorectal cancer. Dis Colon Rectum 2006;49:319-329.
28. Louwman WJ, Aarts MJ, Houterman S, et al. A 50% higher prevalence of life-shortening chronic conditions among cancer patients with low socioeconomic status. Br J Cancer 2010;103:1742-1748.
29. Waitzman NJ, Smith KR. Phantom of the area: poverty-area residence and mortality in the United States. Am J Public Health 1998;88:973-976.
30. Rhoads KF, Ackerson LK, Jha AK, Dudley RA. Quality of colon cancer outcomes in hospitals with a high percentage of Medicaid patients. J Am Coll Surg 2008;207:197-204.
31. Edge S, Byrd DR, Compton CC, et al, ed. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010.
32. van Walraven C, Austin PC, Jennings A, et al. A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data. Med Care 2009;47:626-633.
33. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care 1998;36:8-27.
34. Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004;159:702-706.
35. Ayanian JZ, Zaslavsky AM, Fuchs CS, et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol 2003;21:1293-1300.
36. Dominitz JA, Samsa GP, Landsman P, Provenzale D. Race, treatment, and survival among colorectal carcinoma patients in an equal-access medical system. Cancer 1998;82:2312-2320.
37. Koroukian SM. Assessment and interpretation of comorbidity burden in older adults with cancer. J Am Geriatr Soc 2009;57(Suppl 2):S275-278.
38. Lemmens VE, Janssen-Heijnen ML, Verheij CD, et al. Co-morbidity leads to altered treatment and worse survival of elderly patients with colorectal cancer. Br J Surg 2005;92:615-623.
39. Luo R, Giordano SH, Zhang DD, et al. The role of the surgeon in whether patients with lymph node-positive colon cancer see a medical oncologist. Cancer 2007;109:975-982.
40. Neugut AI, Fleischauer AT, Sundararajan V, et al. Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: a population-based study. J Clin Oncol 2002;20:2643-2650.
41. Sarfati D, Hill S, Blakely T, et al. The effect of comorbidity on the use of adjuvant chemotherapy and survival from colon cancer: a retrospective cohort study. BMC Cancer 2009;9:116.
42. Schrag D, Cramer LD, Bach PB, Begg CB. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 2001;93:850-857.
43. Schrag D, Gelfand SE, Bach PB, et al. Who gets adjuvant treatment for stage II and III rectal cancer? Insight from surveillance, epidemiology, and end results - Medicare. J Clin Oncol 2001;19:3712-3718.
44. Sundararajan V, Grann VR, Jacobson JS, et al. Variations in the use of adjuvant chemotherapy for node-positive colon cancer in the elderly: a population-based study. Cancer J 2001;7:213-218.
45. Hodgson DC, Fuchs CS, Ayanian JZ. Impact of patient and provider characteristics on the treatment and outcomes of colorectal cancer. J Natl Cancer Inst 2001;93:501-515.
46. Meyerhardt JA, Catalano PJ, Haller DG, et al. Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol 2003;21:433-440.
47. Potosky AL, Harlan LC, Kaplan RS, et al. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol 2002;20:1192-1202.
48. Abraham NS, Gossey JT, Davila JA, et al. Receipt of recommended therapy by patients with advanced colorectal cancer. Am J Gastroenterol 2006;101:1320-1328.
49. Fleming ST, Mackley HB, Camacho F, et al. Clinical, sociodemographic, and service provider determinants of guideline concordant colorectal cancer care for appalachian residents. J Rural Health 2014;30:27-39.
50. Greenberg CC, Lipsitz SR, Neville B, et al. Receipt of appropriate surgical care for Medicare beneficiaries with cancer. Arch Surg 2011;146:1128-1134.
51. Luo R, Giordano SH, Freeman JL, et al. Referral to medical oncology: a crucial step in the treatment of older patients with stage III colon cancer. Oncologist 2006;11:1025-1033.
52. VanEenwyk J, Campo JS, Ossiander EM. Socioeconomic and demographic disparities in treatment for carcinomas of the colon and rectum. Cancer 2002;95:39-46.
53. Khrizman P, Niland JC, ter Veer A, et al. Postoperative adjuvant chemotherapy use in patients with stage II/III rectal cancer treated with neoadjuvant therapy: a national comprehensive cancer network analysis. J Clin Oncol 2013;31:30-38.
54. Ko CW, Kreuter W, Baldwin LM. Persistent demographic differences in colorectal cancer screening utilization despite Medicare reimbursement. BMC Gastroenterol 2005;5:10.
55. Ball JK, Elixhauser A. Treatment differences between blacks and whites with colorectal cancer. Med Care 1996;34:970-984.
56. Hershman D, Hall MJ, Wang X, et al. Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer. Cancer 2006;107:2581-2588.
57. Lee AJ, Gehlbach S, Hosmer, et al. Medicare treatment differences for blacks and whites. Med Care 1997;35:1173-1189.
58. Morris AM, Wei Y, Birkmeyer NJ, Birkmeyer JD. Racial disparities in late survival after rectal cancer surgery. J Am Coll Surg 2006;203:787-794.
59. Whitlock EP, Lin JS, Liles E, et al. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2008;149:638-658.
60. Amri R, Bordeianou LG, Sylla P, Berger DL. Impact of screening colonoscopy on outcomes in colon cancer surgery. JAMA Surg 2013:1-7.
61. Brenner H, Chang-Claude J, Seiler CM, et al. Potential for colorectal cancer prevention of sigmoidoscopy versus colonoscopy: population-based case control study. Cancer Epidemiol Biomarkers Prev 2007;16:494-499.
62. Cress RD, Morris C, Ellison GL, Goodman MT. Secular changes in colorectal cancer incidence by subsite, stage at diagnosis, and race/ethnicity, 1992-2001. Cancer 2006;107(5 Suppl):1142-1152.
63. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010;116:544-573.
64. Kahi CJ, Imperiale TF, Juliar BE, Rex DK. Effect of screening colonoscopy on colorectal cancer incidence and mortality. Clin Gastroenterol Hepatol 2009;7:770-775.
65. Siegel RL, Ward EM, Jemal A. Trends in colorectal cancer incidence rates in the United States by tumor location and stage, 1992-2008. Cancer Epidemiol Biomarkers Prev 2012;21:411-416.
66. Bass AJ, Meyerhardt JA, Chan JA, et al. Family history and survival after colorectal cancer diagnosis. Cancer 2008;112:1222-1229.
67. McConnell YJ, Inglis K, Porter GA. Timely access and quality of care in colorectal cancer: are they related? Int J Qual Health Care 2010;22:219-228.
68. Marshall JL, Cartwright TH, Berry CA, et al. Implementation of a performance improvement initiative in colorectal cancer care. J Oncol Pract 2012;8:309-314.
69. Martinez-Donate AP, Halverson J, Simon NJ, et al. Identifying health literacy and health system navigation needs among rural cancer patients: findings from the Rural Oncology Literacy Enhancement Study (ROLES). J Cancer Educ 2013;28:573-581.
70. Napoles-Springer AM, Livaudais JC, Bloom J, et al. Information exchange and decision making in the treatment of Latina and white women with ductal carcinoma in situ. J Psychosoc Oncol 2007;25:19-36.
71. Leighl NB, Shepherd HL, Butow PN, et al. Supporting treatment decision making in advanced cancer: a randomized trial of a decision aid for patients with advanced colorectal cancer considering chemotherapy. J Clin Oncol 2011;29:2077-2084.
72. Freund KM, Battaglia TA, Calhoun E, et al. Impact of patient navigation on timely cancer care: the Patient Navigation Research Program. J Natl Cancer Inst 2014;106:dju115.
73. Ell K, Vourlekis B, Xie B, et al. Cancer treatment adherence among low-income women with breast or gynecologic cancer: a randomized controlled trial of patient navigation. Cancer 2009;115:4606-4615.
74. Petereit DG, Molloy K, Reiner ML, et al. Establishing a patient navigator program to reduce cancer disparities in the American Indian communities of Western South Dakota: initial observations and results. Cancer Control 2008;15:254-259.
75. Schwaderer KA, Proctor JW, Martz EF, et al. Evaluation of patient navigation in a community radiation oncology center involved in disparities studies: a time-to-completion-of-treatment study. J Oncol Pract 2008;4:220-224.
76. Donelan K, Mailhot JR, Dutwin D, et al. Patient perspectives of clinical care and patient navigation in follow-up of abnormal mammography. J Gen Intern Med 2011;26:116-122.
77. Fillion L, de Serres M, Cook S, et al. Professional patient navigation in head and neck cancer. Semin Oncol Nurs 2009;25:212-221.
78. Skrutkowski M, Saucier A, Eades M, et al. Impact of a pivot nurse in oncology on patients with lung or breast cancer: symptom distress, fatigue, quality of life, and use of healthcare resources. Oncol Nurs Forum 2008;35:948-954.
79. Swanson J, Koch L. The role of the oncology nurse navigator in distress management of adult inpatients with cancer: a retrospective study. Oncol Nurs Forum 2010;37:69-76.
80. The Patient Protection and Affordable Care Act, Pub L No. 111-148, 124 Stat 119.
81. Hines RB, Chatla C, Bumpers HL, et al. Predictive capacity of three comorbidity indices in estimating mortality after surgery for colon cancer. J Clin Oncol 2009;27:4339-4345.
82. American Cancer Society. Cancer Facts & Figures 2011. Atlanta, GA: American Cancer Society; 2011. Available at: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-029771.pdf. Accessed December 2, 2014.
83. Etzioni DA, El-Khoueiry AB, Beart RW Jr. Rates and predictors of chemotherapy use for stage III colon cancer: a systematic review. Cancer 2008;113:3279-3289.
84. Weiser MR, Gonen M, Chou JF, et al. Predicting survival after curative colectomy for cancer: individualizing colon cancer staging. J Clin Oncol 2011;29:4796-4802.
85. Driscoll JJ, Rixe O. Overall survival: still the gold standard: why overall survival remains the definitive end point in cancer clinical trials. Cancer J 2009;15:401-405.
86. Saad ED, Buyse M. Overall survival: patient outcome, therapeutic objective, clinical trial end point, or public health measure? J Clin Oncol 2012;30:1750-1754.